FDA raises concerns about ultra-long acting insulins given green light in Europe and Japan

BMJ. 2012 Oct 30:345:e7323. doi: 10.1136/bmj.e7323.
No abstract available

Publication types

  • News

MeSH terms

  • Cardiovascular Diseases / chemically induced*
  • Drug Approval
  • Europe
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Insulin, Long-Acting / adverse effects*
  • Japan
  • United States
  • United States Food and Drug Administration

Substances

  • Hypoglycemic Agents
  • Insulin, Long-Acting